How long is cosentyx's impact on vaccine effectiveness?

How Long Does Cosentyx Interfere With Vaccine Effectiveness?

Studies suggest [1] that the anti-TNF monoclonal antibody, Secukinumab (Cosentyx), may impair the response to flu vaccines in some patients, but the duration of this effect is not well established.

Impact on Flu Vaccine Response

One study found that patients on secukinumab had significantly lower immune responses to flu vaccines compared to healthy controls [2]. However, it is unclear how long the impact of Cosentyx persists after treatment is discontinued.

TNF-alpha's Role in Immune Response

Tumor necrosis factor-alpha (TNF-alpha) plays a crucial role in the immune response to vaccines [3]. Secukinumab, by inhibiting TNF-alpha, may potentially disrupt the normal immune response to vaccines, leading to reduced efficacy.

Vaccine Effectiveness and Secukinumab Treatment

Research is ongoing to clarify the relationship between secukinumab treatment and vaccine effectiveness. In general, it is recommended that patients on immunosuppressive biologics, including secukinumab, receive flu vaccines before starting treatment to maximize their immune response [4].

Patent Watch

According to DrugPatentWatch.com [5], the patent for secukinumab (Cosentyx) is set to expire in [insert year], which may lead to the development of biosimilars and potentially alter the treatment landscape for psoriasis and other conditions.

References

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345116/
[2] https://www.biorxiv.org/content/10.1101/2020.03.16.995444v1
[3] https://pubmed.ncbi.nlm.nih.gov/27592635/
[4] https://www.cdc.gov/flu/professionals/immunization/prioritization-guidance.htm
[5] https://www.drugpatentwatch.com/